Companies › AB Science
2 active drug programs in 2 registered trials: 1 Phase 3, 1 Phase 1; Neurology, Oncology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Masitinib Fibroblast growth factor receptor 3 inhibitor; Stem cell growth factor receptor inhibitor; Platelet-derived growth factor receptor inhibitor | FGFR3, KIT, PDGFRB, PDGFRA | Phase 3 | Amyotrophic Lateral Sclerosis | Dec 2027 |
| AB8939 | – | Phase 1 | Acute Myeloid Leukemia Refractory | Dec 2026 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05211570 | AB8939 | Phase 1 | Acute Myeloid Leukemia Refractory | Oncology | Dec 2026 |
| NCT03127267 | Masitinib | Phase 3 | Amyotrophic Lateral Sclerosis | Neurology | Dec 2027 |
Advenchen Laboratories TransThera Sciences (Nanjing) SK Life Science Luye Pharma Group Cogent Biosciences
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.